MXPA06000005A - Infant or follow-on formula - Google Patents

Abstract

The formula of the invention, intended both for infants and young children, comprises modified sweet whey proteins free or almost free of CGMP, and at least one probiotic. The invention also pertains to methods for promoting physical development, improving gastro intestinal comfort and developing a healthy gut microflora in infants or young children by fully or partly feeding them with the said formula.

Description

CHILD OR FOLLOWING FORMULA Field of the invention. The present invention relates to a nutritional composition designed for infants and / or young children, as well as to methods for improving gastrointestinal well-being, developing a healthy intestinal microflora and promoting the physical development of infants and / or young children by partially or totally feeding to infants or children with the aforementioned nutritional composition.

Environment of the invention. The composition of human milk serves as a valuable reference for improving infant formula. However, human milk contains living cells, hormones, active enzymes, immunoglobulins and components with unique molecular structures that can not be replicated in an infant formula. Unlike human milk, infant formula can remain stable on the shelf for up to thirty-six (36) months. These fundamental differences between human milk and infant formula often impose differences in composition to achieve similar clinical outcome.

The study of the components of human milk has stimulated many investigations as to which constituents can be added to an improved infant formula. The greater knowledge of the composition of human milk offers the opportunity to design infant formula that is closer in its composition to human milk. However, it is increasingly apparent that infant formula can never exactly duplicate human milk. Many constituents in human milk are bioactive and, because of the synergies between these components, there is little reason to believe that the same compound would have the same bioactivity in infant formula. The similarity of this possibility also decreases when considering the impact of heat treatment for sterilization and long-term storage of the formula.

The composition of human milk differs appreciably from that of other species and much attention has been paid to the various components. Several researchers have reported on the nucleotide content of human milk. Numerous publications have also discussed various lipids, oils or mixtures of fats for use in artificial nutrition for human infants.

There is a need for new formulas, which provide the infant or young child with a nutritional contribution with a unique combination of protective nutrients, especially to ensure development and patterns similar to those of breastfed infants, thus resulting in characteristics of similar health in childhood and adulthood.

Description of the invention The present invention therefore belongs to formulas designed for both infants and young children. The formula of the invention comprises containing a protein source, a lipid source, a carbohydrate source and a probiotic, wherein at least 40% of the proteins are modified whey sweet proteins that do not comprise reduced CGMP or CGMP .

The present invention also provides a method for promoting the physical development of an infant or a young child, which consists in feeding the infant or the child totally or partially with that formula.

The present invention also provides a method for improving the gastrointestinal well-being of an infant or a young child, which consists in feeding the infant or the child totally or partially with that formula.

The present invention also provides a method for developing a healthy intestinal microflora in an infant or a young child, which consists in feeding the infant or the child totally or partially with that formula.

Detailed description of the invention. In the present specification, the following words are given a definition that must be taken into account when reading and interpreting the description, the examples and the claims.

Infant: according to the Directive of the Commission 91/321 / EEC of May 14, 1991, on infant formulas and follow-up formulas, article 1.2 (a), the term "infants" means children under 12 months of age. This definition is adopted in the present specification.

Young children: according to the Directive of the Commission 91/321 / EEC of May 14, 1991, on infant formulas and follow-up formulas, article 1.2 (b), the term "young children" means children with ages between one and three years. This definition is adopted in the present specification.

Infant formulas: according to the Directive of the Commission 91/321 / EEC of May 14, 1991, on infant formulas and follow-up formulas, article 1.2 (c), the term "infant formulas" means food products designed for the Special nutritional use of infants during the first four to six months of life and that satisfy by themselves the nutritional requirements of this category of people. This definition is adopted in the present specification. It should be understood that infants can be fed only with infant formulas, or that infant formula can be used by the caregiver as a supplement to human milk. It is synonymous with the expression, widely used, "start formula".

Follow-up formulas: according to the Directive of the Commission 91/321 / EEC of May 14, 1991, on infant formulas and follow-up formulas, article 1.2 (d), the term "follow-up formulas" means designed food products for the particular nutritional use of infants with more than four months of age and who constitute the main liquid element in a progressively diversified diet of this category of persons. This definition is adopted in the present specification.

Probiotic: according to the publication Probiotics in Man and Animáis, J. Appl Bacteriol., 66: 365-378, a probiotic is defined as a live microbial food supplement that beneficially affects the host animal by improving its intestinal microbial balance.

According to a first aspect of the invention, a nutritional formula for infants (including a start composition) or young children is provided. As already mentioned, an object of the invention is to provide a unique combination of protective nutrients that ensure development and metabolic patterns similar to those of breastfed infants, with the intention of allowing them to enjoy similar health characteristics in childhood and adulthood.

The formulas of the invention have a reduced load of immature organs; and favor the natural development of Bifidobacteria and other beneficial microflora in the large intestine as in breastfed infants.

Dietary protein provides the essential amino acids for protein synthesis and the development and quality of the protein are as important as the amount of protein. Until recently it was believed that, in order to supply sufficient essential amino acids, formulas based on cow's milk needed a protein content significantly higher than that of reference human milk. The protein content of the formulas adapted from regular whey are in the range of from 2.1 to 2.6 g for 100 kcal, while the content of human milk is in the range of from 1.4 to 1.8 g for 100 kcal. Excess protein intake can induce metabolic stress in the infant's organs that have not fully developed. Following pediatric recommendations to decrease the protein density of infant formulas, clinical trials have reported infant formulas that contain protein densities between 1.6 and 2.0 g / 100 kcal. -Nevertheless, these attempts to decrease the protein content in a formula that uses cow's milk protein sources or mixed the currently available fractions -casein and whey-, even when they demonstrated that the principle was conceivable, they failed to reproduce all the indexes of the metabolism of the human milk protein or to assure the satisfactory development of the infants. For example, the results have shown a global plasma amino acid pattern different from that of breastfed infants, depressed plasma tryptophan levels, elevated plasma threonine levels, developmental delay, and increased energy intake, suggesting Increased fat deposition that may be responsible for obesity in later life.

However, if the amino acid pattern of an infant formula based on cow's milk can be made closer to that of human milk, the protein content of that formula can be lowered to resemble the reference. A mixture of protein of unique amino acid composition, which allows the adaptation of the amount of protein to a level close to the average content of human milk, has been developed according to one aspect of the present invention.

The protein fraction in cow's milk is a mixture of several proteins, all of which have a different amino acid profile. The caseino-glyco-macropeptide (CGMP) is a protein found in this fraction. It comes from the kappa-casein that is divided by proteolytic cleavage in 2/3 of para-kappa-casein, an insoluble fraction that remains in the casein fraction and 1/3 of CGMP, a soluble fraction that is found in the fraction of the whey. In EP 880902 an original process of fractionation of whey proteins has been developed and explained; this process allows the removal of virtually all the CGMP (a fraction rich in threonine and poor in tryptophan) from bovine serum, thereby increasing the proportion of alpha-lactalbumin (a fraction very rich in tryptophan). Combining this modified sweet whey (MS) with skimmed milk, and with the addition of some free L-histidine and L-arginine (to achieve the minimum amounts of these amino acids required by the EC Directive), the The protein source of the formula according to the invention has an amino acid profile much closer to that of human milk, characterized in particular by the comparable levels of tryptophan and threonine, allowing the adaptation of this protein content to that of human milk. .

The nutritional value of this protein mixture has been measured in rats. The results show (see Table 1) that this formulation has a Protein Efficiency Ratio (PER), a nitrogen digestibility, a Biological Value (BV) and a Net Protein Utilization (NPU), comparable to those of the standard formulas adapted from the whey.

Table 1 In addition, rats fed a formulation containing MSW showed significantly lower levels of threonine in plasma and increased levels of tryptophan in plasma, compared to rats fed standard formulas adapted from whey.

The protein content of the formulas according to the present invention is preferably not more than 2 g / 100 kcal, more preferably less than 1.85, most preferably between 1.8 and 1.85 g / 100 kcal. This level is in line with the recent data that evaluate the protein requirements during the first years of -lívida, which have shown that the recommendations for optimal protein intakes are lower than what had been reported in the past.

To ensure optimal synthesis of the protein, and therefore optimum development, essential and semi-essential amino acids (i.e., essential only during childhood) need to be supplied in the same amounts as in human milk. The formulas according to the invention are preferably either enriched with whey (ratio of casein / whey established at around 40/60) or, more preferably, whey predominating (casein / whey ratio). milk preferably set at 30/70 or even more, as much as 20/80). A preferable amino acid profile for the formulas according to the invention is comparable to that of human milk (see Table 2).

Table 2 All values corrected to 40% of NH3 * essential amino acids ** semi-essential amino acids Preferably, the only carbohydrate source of the composition according to the present invention is lactose. Carbohydrates are an important source of energy in the diet of the newborn infant. Lactose is the natural carbohydrate in human milk. Most healthy infants can properly digest lactose. further, lactose is associated with the acidity of feces and with the development of a Bifidobacteria and the predominant bacilli of the microflora in the large intestine similar to those of breastfed babies. It is thought that it is important to suppress the development of undesirable bacteria in the large intestine.

In addition, lactose has been shown to improve the absorption and retention of calcium and probably other minerals. In a recent study, it has been shown that calcium absorption is 10% higher from the formula containing lactose compared to the same formula in which lactose has been replaced by glucose polymers.

As mentioned above, the formulas according to the invention comprise at least one probiotic, to offer all infants, whatever their mode of birth or their hygienic environment, the advantages of a protective intestinal flora.

The preferable probiotics are those that are safe as a whole, are producing cultures of lactic acid L (+) and have acceptable shelf life for products such as infant and follow-up formulas that are required to remain stable and effective for up to 36 months . Examples of preferable probiotics are: Bifidobacterium lactis, sold first by Christian Hansen company; Streptococcus thermophilus, which is provided under the name TH4 in Chr. Hansen, Denmark; Lactobacillus paracasei rhamnosus GG (ATCC 53103) provided by Valió Oy, Finland; Bifidobacterium longum BB536, provided by Morinaga Milk Industry Co. Ltd., Japan.

The probiotics according to the present aspect of the invention are preferably present in an amount of from 106 to 109 cfu / grams of dry product, preferably from 105 to 108 cfu / g, and even more preferably from 2 * 107 cfu / grams of dry product The composition according to the present invention comprises at least one probiotic strain, but combinations of different strains can also be used, particularly in the follow-up formulas. If that combination is to be used, it will preferably include at least one Bifidobacterium and at least one Lactobacillus. A particularly preferable combination is that of Bifidobacterium longum BB536 and Lactobacillus paracasei rhamnosus GG.

The formulas of the present invention also comprise a lipid source. Fat provides about half the dietary energy and is the largest storage of energy in the bodies of infants and young children. Currently, there is a growing interest in the quality of dietary lipid supply during childhood as a major determinant of growth, visual and neural development, and long-term health. Therefore, the selection of the dietary lipid supply during the first stage of life is considered to be of great importance.

Because of the small size of their stomach and their limited tolerance of hypertonic foods, infants require a concentrated source of energy. Of the 3 nutrients that supply energy, fat provides 9 kcal / gram, i.e., more than twice the energy present in carbohydrates or proteins. Most experts recommend that in infant and follow-up formulas, fat should provide from 30% to 55% of total energy. Preferably, the fats used in the formulas of the invention are predominantly vegetable fats. However, whey and skim milk naturally contain traces of milk fat, and then a very small percentage of milk fat seems to be present.

The fatty acid composition of the diet determines the fatty acid composition of all tissues, including storage tissues. The fat mixture used in the formulas of the invention therefore preferably has a general fatty acid composition as close as possible to that of human milk, to ensure similar plasticity of the membranes and the same mobilization of energy in the case of growing needs. Therefore, the preferable mixture of fat supplies the essential fatty acids (linoleic and linoleic acids), as well as the adequate amounts of oleic acid, palmitic acid, lauric acid and myristic acid.

Human milk contains docosahexaenoic acid (DHA) and arachidonic acid (ARA) and therefore breastfeeding provides preformed LC-PUFAf infants. The DHA content of human milk varies considerably within populations and is strongly influenced by the maternal diet. Overall, the DH content of the milk of mothers who consume Western diets is in the range of 0.1 to 0.4%, with an average of 0.25%, while in mothers who consume non-Western diets, 1 DHA content of the Milk is higher, in the range of 0.1 to 1.4%, with an average of 0.6%. However, amounts of 0.2 to 0.3% are generally accepted as representative. The ARA content of human milk is less influenced by the diet than that of DHA. Overall, the ARA content of the human milk of mothers who consume Western diets is in the range of 0.2% to 0.7%, with an average of 0.45%, while in mothers who consume non-Western diets, the content of ARA It is in the range of 0.4 to 1.2%, with an average of 0.6%. Both levels of DHA and ARA are influenced by the duration of lactation and tend to decrease from colostrum to transition milk and mature.

Accordingly, the lipid source of the present invention preferably also comprises at least one preformed LC-PUFA such as DHA. The source of the DHA can be a natural fish oil that also provides eicosapentaenoic acid (EPA) with a DHA / EPA ratio > 4. Along with DHA, the lipid source can also include ARA, for example of fungal origin such as from Mortierella alpina.

The formulas of the invention preferably have a reduced level of electrolytes compared to infant and growth formulas. For example, the ratio Na / K (mmol) can be around 0.4, the ratio (Na + K) / Cl (mraol) can be around 1.8, that of Na + K + Cl can be around 34 and that of (Na + K) -Cl can be around 10.

The formulas according to the present invention preferably have a low phosphate content. Preferably, the calcium content varies between 35 and 45 mg / 100 L, the phosphorus content varies between 15 and 25 mg / mL, and the Ca / P ratio is between 1.4 and 3. The most preferable amounts are indicated in the Table 3 below.

Table 3 Breast milk Invention Cow's milk - values (mg / 100 mL) (mg / 100 ml) average (mg / 100 mL) Calcium 41 120 30 Phosphorus 21 90 15 Ratio Ca / P 2 1.3 2 The formulas according to the invention can also supply essential nutrients that may be needed under particular conditions (eg, taurine, nucleotides, carnitine, selenium).

Taurine is a free amino acid, which is not used to build protein molecules. It has been shown to be involved in many physiological functions, p. ex. , as a tropic factor in the development of the central nervous system, maintaining the structural integrity of the membranes, regulating calcium homeostasis, a neuromodulator and a neurotransmitter. It is also conjugated with bile acids to form bile salts (essential for the formation of micelle and the absorption of fat).

Nucleotides are non-protein nitrogen compounds that contain three characteristic components: a nitrogenous base, a sugar (ribose or deoxyribose), and one or more phosphate groups. The total content of nucleotides in human milk represents 2 to 5% of the non-protein nitrogen. Cow's milk contains lower concentrations of nucieotides than human milk and its nucleotide profile differs markedly from that of human milk. The addition of nucleotides in the present infant formula follows the physiological pattern of nucleotide levels in human milk, with a predominance of easily metabolized pyrimidines on the less desirable purines: the addition of nucleotides to infant formula is safe. The levels of addition are within the range allowed by the Scientific Committee of the European Union for Foods and by the European Directive.

Carnitine is a particular nitrogenous compound, which belongs to a group of food factors known as vitamin-like nutrients. It plays a crucial role in the supply of tissue energy during fetal life and in the neonatal period; facilitating the transport of long chain fatty acids in the mitochondria where beta-oxidation occurs. Fatty acids are not able to pass freely through the mitochondrial wall; the transfer within the mitochondria is governed by at least three enzymatic systems, namely, transferases I and II of carnitine-palmitoyl and translocase of carnitine, in which carnitine participates. Therefore, carnitine is required for proper oxidation of lipid and carnitine deficiency or low intake of carnitine can lead to misuse of fat and altered lipid metabolism, carnitine also has a role in other processes metabolic, such as ketogenesis, lipolysis, and the maintenance of ter ogénesis and nitrogen metabolism. In addition, carnitine has been shown to improve the utilization of medium chain triglycerides in infants. Newborns have relatively low reserves of carnitine and very low activity of the enzyme that catalyzes the last step in the synthesis of carnitine. Therefore newborns are particularly at risk of becoming carnitine-deficient in the absence of an adequate supply of exogenous carnitine. Carnitine is preferably added to infant formulas, to reach a level close to that of human milk.

The formulas according to the invention can be in the form of a powder or a liquid ready to drink. In the case of a powder formula, the following table can be used as a guide (Table 4). However, the amounts can be changed according to the doctor's advice. The introduction of infant formula should be carried out under medical supervision. The standard reconstitution of the formulas according to the invention is 12.9%, i.e., 12.9 g of powder per 90 mL of water, which gives a caloric density of 67 kcal / 100 L.

Table 4 In the case of a liquid ready to drink, special care must be taken to ensure that the probiotic does not accidentally come into contact with the liquid. Preferably, the probiotic is stored as a powder separate from the liquid, and is incorporated and homogenized within the liquid just prior to consumption, e.g. ex. , up to two hours before consumption.

The present invention also relates to a method for promoting the physical development of an infant or a young child, which consists of feeding the infant or the child totally or partially with a formula according to the invention.

The formulas according to the invention have been shown to provide nutritional benefits including better utilization of the protein, an amino acid pattern in plasma close to that of breastfed infants, and adequate growth rates. The improved amino acid profile of the formulas according to the invention results in better utilization of the protein, as shown by the high percentage of nitrogen retention found in infants fed a formula according to the invention, compared to infants fed with a regular formula adapted from whey (see Table 5). As a result, the total amount of total nitrogen remains unchanged.

Table 5: nitrogen balance Plasma amino acids of infants fed a formula according to the invention have been shown to be closer to those of breastfed infants, compared to infants fed standard formulas adapted from whey. In addition, the protein content of the formulas of the invention meets the needs of infants at normal term during the first months of life, without excessive energy intakes or increase in body mass index. Still further, the gains in weight and length of the infants fed with the formulas according to the invention are comparable with those of the breastfed infants. The formulas according to the invention have a reduced charge in the immature organs. Amino acids consumed in excess and not used for protein synthesis accumulate in the blood (hyperaminoacidemias) and are metabolized in the liver within the urea that must be excreted through the kidneys, thereby increasing the burden on the kidneys.

This unnecessary metabolic stress is well illustrated in infants fed standard formulas adapted from whey through plasma amino acid levels and plasma urea levels above those observed in breastfed infants. The lower protein content of the formulas according to the invention obviates the metabolic stress on the infant's immature organs, due to excessive intake of dietary protein. This beneficial effect has been demonstrated: infants fed a formula according to the invention have plasma urea nitrogen concentrations similar to those found in breastfed infants, and significantly lower than those found in infants breastfed with standard formulas adapted from whey. The urea nitrogen in plasma is a very sensitive indicator of the adequacy of protein intake, since higher levels than those of breastfed infants denote unused excess amino acids, while lower levels denote insufficient protein supply . In addition, the modified sweet whey and the probiotic (s) in the formulas according to the invention may have a synergistic effect in the promotion of physical development, particularly when there is also LC-PUFA present.

According to a third aspect of the invention, there is provided a method for improving the gastrointestinal well-being of an infant or a young child, which consists in feeding totally or partially the infant or child with a formula according to the invention. In particular, infants fed with a formula according to the invention have found an improvement in stool consistency, specifically a reduction in the frequency of hard stools. It is thought that this improvement is due to a synergy between the probiotic (s) and the modified sweet whey proteins.

According to another aspect of the present invention, there is provided a method for developing a healthy intestinal microflora in an infant or a young child, which consists in feeding the infant or the child totally or partially with a formula according to the invention.

It is reported that the composition of the intestinal microflora and the population size of the strains are regulated mainly by competition for nutrients and oxygen availability. It is believed that there are factors in breast milk can be bifidogenic, which explains then the ease with which a favorable microflora is established in breastfed infants0 Bifidobacteria, when developed, uses lactose as a substrate to produce lactic and acetic acids that they diminish the intestinal pH until 4-5. The low capacity of regulation of breast milk would allow the maintenance of that low pH, which inhibits the development of anaerobic rotting bacteria and allows the proliferation of Bifidobacteria and lactobacilli that are tolerant 1 acid. Without wishing to be bound by theory, the inventor believes that there is a synergy between the protein source of the formulas according to the invention and the probiotic, so that a microflora similar to that found in breastfed babies is quickly established. and maintained in infants fed with a formula according to the invention.

The reduced phosphate content of the formula according to the first objective of the present invention optimizes bone formation and, together with lactose and low protein content, creates the optimum condition for an intestinal flora with a predominance of Bifidobacteria.

Examples The following examples are illustrative of some of the products and methods for making them that fall within the competence of the present invention. They should not be considered in any way limiting the invention. Changes and modifications can be made with respect to the invention. That is, the skilled person will recognize many variations in these examples to cover a wide range of formulas, ingredients, processing and blends, to rationally adjust the 'naturally occurring levels of compounds' of the invention for a variety of applications.

Example 1. The following example of a preferable formula according to the invention is illustrative only.

Bifidobacterium longum BB 536: 1 x 107 cfu / gram of dry product Lactobacillus paracasei rhamnosus GG: 2 x 107 cfu / gram of dry product Example 2. About 100 infants whose mothers chose not to breastfeed after the 14th day of their lives enrolled in a double-blind, randomized, multi-center clinical trial of two groups. The first group is fed with the formula of Example 1 and the second group is fed a similar formula but without probiotics. The following measurements, which are recognized parameters to evaluate the physical development of the infants, were carried out during 112 days (16 weeks): - average weight gain in g / day, length in the lying state, head circumference. The measures were taken at recruitment, then at 5 weeks, at 8 weeks, at 12 weeks and at 16 weeks (in each case, +/- 1 week), as follows: Weight (approximate 10 grams): infants were weighed without clothes on electronic scales. The same scales were used for all infants in all visits. The electronic scales were calibrated according to the manufacturer's recommendations at the beginning of the study and then every 3 months until the end of the study.

Length in the lying state (with approximation of 1 mm): infants were measured using a standardized length board. At least two people were present to maintain the proper alignment of the body and the total extension of the body with the feet flexed.

Circumference of the head (with approximation of 1 mm): it was obtained using a standard non-elastic measuring tape, covered with plastic. The measurement is taken approximately 2.5 cm above the eyebrows, directly on the largest circumference of the skull.

In addition, regular observations of digestive tolerance are made observing the characteristics of the feces, the incidence of vomiting and regurgitation, the frequency and duration of cramping, as follows: 3 days after recruitment. 3 days before and after the anthropometric measurements at 5 weeks, at 8 weeks and at 12 weeks. 3 days before the end of the anthropometric measurements at 16 weeks.

In addition, the frequency of episodes of morbidity was recorded (number of times that were seen by health professionals plus episodes of illness, particularly gastrointestinal conditions). These observations were made by the caregivers of the infants in a diary provided for this purpose.

It was found that infants fed the formula of the invention showed satisfactory physical development together with improved gastrointestinal well-being (as demonstrated by the digestive tolerance observations detailed above), compared to the control group.

Claims (21)

1. Infant or follow-up formula comprising a protein source, a lipid source, a carbohydrate source and a probiotic, wherein at least 40% of the proteins are modified sweet whey proteins that do not comprise CGMP or that comprise CGMP reduced.

2. Formula according to claim 1, wherein at least 60% of the proteins are modified sweet whey proteins that do not comprise CGMP or comprise reduced CGMP.

3. Formula according to claim 1 or 2, wherein the probiotic is a Bifidobacteria or a Lactobacillus.

4. Formula according to claim 3, wherein the Bifidobacterium is Bifidobacterium longum BB 536.

5. Formula according to claim 3, wherein the Lactobacillus is Lactobacillus paracasei rhamnosus GG.

6. Formula according to claim 1 or 2, which contains both a Bifidobacterium and a Lactobacillus. .

Formula according to claim 6, wherein the Bifidobacterium is Bifidobacterium longum BB 536 and the Lactobacillus is Lactobacillus paracasei rhamnosus GG.

8. Formula according to any of the preceding claims, wherein the proteins are intact.

9. Formula according to any of the preceding claims, wherein the proteins are partially hydrolyzed.

10. Formula according to any of the preceding claims, wherein the proteins are present in a maximum proportion of 2g / 100 kcal, preferably 1.85, most preferably between 1.8 and 1.85 g / 100 kcal.

11. Formula according to the preceding claim, wherein the whey proteins with reduced CGMP represent at least 60% of the total proteins, preferably at least 70% of the total proteins.

12. Formula according to any preceding claim, further comprising at least one LC-PUFA.

13. Formula according to claim 12, wherein the LC-PUFA comprises DHA, associated or not with ARA.

14. Formula according to one of claims 1 to 13, which also has a low amount of electrolytes.

15. Method for promoting the physical development of an infant or a young child, consisting of feeding the infant or child in whole or in part with a formula comprising a source of protein, a source of lipids, a source of carbohydrates and at least one probiotic, where at least 40% of the proteins are whey proteins that do not comprise CGMP or that comprise reduced CGMP.

16. Method according to claim 15, using a formula according to any of claims 1 to 14.

17. Method according to claim 15 or claim 16, wherein the physical development of the infant or child is characterized by a reduced load on the immature organs.

18. Method to improve the gastrointestinal well-being of an infant or a young child, which consists in feeding the infant or child in whole or in part with a formula comprising a protein source, a source of lipids, a source of carbohydrates and less a probiotic, where at least 40% of the proteins are whey proteins that do not comprise CGMP or comprise reduced CGMP.

19. Method according to claim 18, using a formula according to any of claims 1 to 14.

20. Method for developing a healthy intestinal microflora in an infant or a young child, consisting of feeding the infant totally or partially. or the child with a formula comprising a protein source, a lipid source, a carbohydrate source and at least one probiotic, wherein at least 40% of the proteins are whey proteins that do not comprise CGMP or comprise CGMP reduced.

21. Method according to claim 20, using a formula according to any of claims 1 to 14.